BioSpace News Archive

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the Company hired scientific luminary and MacArthur Fellowship winner, Kevin Eggan, Ph.D., as Group Vice President, Head of Research and Early Development, effective today.

The results of CONTESSA, a Phase 3 study of tesetaxel in the treatment of patients with metastatic breast cancer, have been selected for an oral presentation at the 2020 SABCS, to be held virtually December 8-11, 2020. The presentation details are as follows: Date: December 11, 2020 Time: 9:00am CT Session: General Session 4 Title: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capeci

AVACEN Medical (AVACEN) announced the completion and results from the second part of its sponsored 50 person study of glucose tolerance in Type 2 diabetics. The double-blind randomized controlled pilot study with crossover design focus

NeuPath Health Inc. (TSXV:NPTH) (“NeuPath” or the “Company”), Canada’s largest provider of chronic pain management services, announced today an initiative to expand the Company’s digital health capabilities. Pivot Design Group (“Pivot”) – a leading Toronto boutique strategic design and communications agency specializing in service design, user experience design and communication design – will work with NeuPath

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that its Chief Executive Officer, Steven Engle, will present a company update at the BIO Investor Forum, being held virtually on October 13-15, 2020. This presentation will be available on demand for BIO Investor attendees. BIO is the world’s largest trade ass

Previously presented preclinical findings show FX301 provided greater sustained, post-operative analgesic effect with no significant impairment in motor function compared to liposomal bupivacaine and placebo BURLINGTON, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the podium presentation of preclinical efficacy and pharmacokinetic (PK) data for FX301, its locally administered peripheral nerve block candidate for control of post-operat

The Gold Standard Diagnostics Group (GSD) today announced the immediate availability of their two new Lyme IgG and Lyme IgM EIA kits for detection of antibodies against Lyme disease causing bacteria. The two assays give laboratories a more diverse arsenal of testing methodologies that allows them to achieve more reliable results. The assays are available immediately in the US. The separate IgG and IgM assays provide la

- Concurrent development program compares Kodiak’s long-acting anti-VEGF antibody biopolymer conjugate KSI-301 to standard of care in all major retinal disease indications: wet AMD, DME, and RVO. - Kodiak also announces completion of U.S. patient enrollment in DAZZLE, its ongoing Phase 2b/3 study of KSI-301 in wet AMD. - Phase 1b durability data continue to improve as they mature further: 72% of wet AMD patients and 79% of DME patients have now achieved a 6-month or longer tr

Three-stage research program will leverage GoodCell’s Pathogen Susceptibility Testing Platform using NYBC’s moderate-to-severe COVID-19 patient samples to identify patients at increased risk of adverse clinical outcomes

HDT-301 vaccine for COVID-19 preparing for IND filing Expanding team towards clinical development for multiple programs SEATTLE--( BUSINESS WIRE )-- HDT Bio Corp., a biotechnology company enabling global access to immunotherapies for oncology and infectious disease, has announced the close of its seed financing round totaling ~$3 million. The round was co-led by Zoic Capital and joined by angel investors from multiple biotechnology h